projects:workgroups:clinicalstudy
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
projects:workgroups:clinicalstudy [2019/02/08 19:47] croeder [Clinical Trial WG] |
projects:workgroups:clinicalstudy [2024/01/15 15:59] (current) zhen [Meetings] |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| - | ====== Clinical Trial WG ====== | + | ====== Clinical Trials Working Group ====== |
| <WRAP box justify round> | <WRAP box justify round> | ||
| - | **Objective:** Understand clinical trial use cases where the OHDSI platform & ecosystem can aid trials in any aspect, and assist in driving updates in OHDSI tools to support. This might be to represent data from interventional trial or observational study in OMOP CDM, might include enabling feasibility analysis, might include trial data collection, supporting biostatistics, or delivering real-world evidence to help trialists, or other. | + | **Objective**: To allow adequate representation of clinical trial data in OMOP. |
| - | **Project Lead:** Shawn Dolley (ping on OHDSI forum or shawn@shawndolley.com) | + | **First use case**: To convert clinical trial data in [[https://www.cdisc.org/standards/foundational/sdtm|CDISC SDTM]] format to [[https://www.ohdsi.org/data-standardization/the-common-data-model/|OMOP]], with a view to allowing trial planning optimization. |
| - | **Members:** | + | **Approach**: We advocate minimum changes to the OMOP CDM and Standardized Vocabularies because we want to ensure minimum impact on OHDSI tools like Atlas, whilst providing a value-add SDTM-to-OMOP conversion with minimum data loss. We have proposed conventions introducing new concepts and modifiers, but no new CDM tables; and providing guidance for ETL developers where appropriate. Our proposals were originally built on OMOP CDM v6 and the Oncology extension, with v5.3 backward compatibility. In a new v5.4 the additions from the Oncology extension became standard, which made our changes minimal, thereby, making our proposals fully compatible with v5.4. |
| - | * Andrew Williams, PhD, Tufts | + | |
| - | * Rupa Makadia, PhD, Janssen | + | |
| - | * Vojtech Huser, PhD, NIH | + | |
| - | * Chris Roeder, MS, Colorado | + | |
| - | * Thomas Falconer, MS, Columbia | + | |
| - | * Josh Ransom, PhD, Medidata | + | |
| - | * Ryan Li, Columbia | + | |
| - | **Start Date:** 2019 (this started as 'Clinical Study' working group in 2016 and was dormant) | + | **Status**:\\ |
| + | - 2022: CTWG was given access to 20 Vivli clinical study packages in the SDTM format. The CTWG team is doing an inventory of those study packages in order to prioritize SDTM-to-OMOP mappings. The existing CTWG guidance topics will be further assessed and new ones identified where necessary. \\ | ||
| + | - 2021: CTWG did an assessment of clinical trial data providers where SDTM data could be accessed. This eventually led to discussions with Vivli (i.e., general data usage agreements and platform feasibility evaluation). \\ | ||
| + | - 2020: Used a synthetic representation of the CDISC SDTM data via PHUSE Test Data. Initial guidance topics were codified but require further testing with diverse real world SDTM data. The CTWG proposals submitted to the OHDSI community in July 2020.\\ | ||
| + | </WRAP> | ||
| - | **Repository:** To be organized soon. | ||
| - | </WRAP> | ||
| + | ==== Important Links ==== | ||
| + | Conventions proposal submitted to OHDSI\\ | ||
| + | https://github.com/OHDSI/CommonDataModel/issues/358 | ||
| + | |||
| + | Group GitHub repository\\ | ||
| + | https://github.com/OHDSI/ClinicalTrialsWGETL | ||
| + | |||
| + | Recent WG Updates: [[https://youtu.be/pWW72a9A5YE|Nov. 2022 Presentation]]; [[https://youtu.be/ctPADsAoYpM|Oct. 2021 Presentation]] and [[https://ohdsiorg.sharepoint.com/:b:/s/Workgroup-Clinicaltrials/EXbVRrl7hQNEiPhC48Zx0t4BfILfVjMiW85MtWBmGHRzFA?e=nThgMV|Slides]] | ||
| + | ---- | ||
| ==== Meetings ==== | ==== Meetings ==== | ||
| + | {{:projects:workgroups:ct_wg_ohdsi2021fallsymp.png?direct&300|}} | ||
| + | |||
| + | **Spring 24 Schedule**: \\ | ||
| + | Bi-weekly on Fridays, 8:30AM PT/10:30AM CT/11:30AM ET/4:30PM UK/11:30PM CST, from Jan. 19th;\\ | ||
| + | |||
| + | *** Note on accessing Teams channel above:**\\ | ||
| + | * If you use the Teams desktop app and have multiple accounts, ensure you are already in the OHDSI Teams account before clicking the link above\\ | ||
| + | * Alternatively, select the "web app" button in the link above for accessing meetings on your browser\\ | ||
| + | |||
| + | ---- | ||
| + | |||
| + | ==== Membership ==== | ||
| + | |||
| + | **WG co-leads**: | ||
| + | Mike Hamidi, Pfizer, US (Kamiar.Hamidi@pfizer.com), | ||
| + | Tom Walpole, ZS Associates, US, | ||
| + | and | ||
| + | Zhen Lin, Memorial Hermann TMC | Robot Bacon, US (Zhen.Lin@ohdsi.org) | ||
| - | **Forum links:** | ||
| - | |||
| - | **Current:** Dial-in info below... | ||
| - | **Old/ Archive** | + | **Active members**\\ |
| - | * http://forums.ohdsi.org/t/omop-cdm-and-clinical-trials/2109 | + | |
| - | * http://forums.ohdsi.org/t/requirements-for-clinical-study-trial-data-in-ohdsi/3202 | + | |
| - | **Specs:** | + | ^ Name ^ Organization ^ Location ^ ^ |
| + | | Chidi Asuzu | | USA | | | ||
| + | | Rebecca Baker | CDISC | Austin, TX, USA | | | ||
| + | | Ian Braun | Critical Path Institute | Tucson, AZ, USA | | | ||
| + | | Melissa Cook | Essex Management | Boston, MA, USA | [[http://www.linkedin.com/in/mkcook|{{:wiki:linkedinicon.png?20}}]] | | ||
| + | | Diane Corey | Critical Path Institute | Tucson, AZ, USA | | | ||
| + | | Shital Desai | | USA | | | ||
| + | | Kerry Goetz | National Institute of Health; \\ National Eye Institute | Bethesda, MD, USA | [[https://www.linkedin.com/in/kerrygoetz/|{{:wiki:linkedinicon.png?20}}]] | | ||
| + | | Priya Gopal | Flatiron Health | New York, NY, USA | | | ||
| + | | Mike Hamidi | Pfizer | USA | [[https://www.linkedin.com/in/kamiar-mike-hamidi-0a908164/|{{:wiki:linkedinicon.png?20}}]] | | ||
| + | | Dan Hartley | | USA | | | ||
| + | | Ying Huang |National Institute of Health | USA | | | ||
| + | | Asiyah Yu Lin | National Institute of Health | Bethesda, MD, USA | | ||
| + | | Zhen Lin | MH-TMC/Robot Bacon | Houston, TX, USA | [[https://www.linkedin.com/in/zhen-lin/|{{:wiki:linkedinicon.png?20}}]], [[https://twitter.com/zhenLinPhDRN|{{:wiki:twittericon.png?20}}]] | | ||
| + | | Zhixin Lun | University of Colorado Anschutz Medical Campus | Aurora, CO, USA | | | ||
| + | | Terrence McHugh | Critical Path Institute | Tucson, AZ, USA | | | ||
| + | | Priya Meghrajani | Talosix | Seattle, WA, USA | | | ||
| + | | Pam Nesbitt | | USA | | | ||
| + | | Paul Orona | | USA | | | ||
| + | | Daniel Olson | Critical Path Institute | Tucson, AZ, USA | | | ||
| + | | Katy Sadowski | TrialSpark | New York, NY, USA | | | ||
| + | | Philip Solovyev | Odysseus Data Services Inc. | Vilnius, Lithuania | [[https://www.linkedin.com/in/filippsolovev|{{:wiki:linkedinicon.png?20}}]] | | ||
| + | | Cynthia Sung | OHDSI | Seattle, WA, USA | [[https://www.linkedin.com/in/cynthia-sung-phd-fcp-ba01703/|{{:wiki:linkedinicon.png?20}}]] | | ||
| + | | Ramona Walls | Critical Path Institute | Tucson, AZ, USA | [[https://www.linkedin.com/in/ramona-walls-41aa7599/|{{:wiki:linkedinicon.png?20}}]], [[https://twitter.com/Ramona_Walls|{{:wiki:twittericon.png?20}}]], [[https://github.com/ramonawalls|{{:wiki:githubicon.png?15}}]] | | ||
| + | | Tom Walpole | ZS Associates | Princeton, NJ, USA | | | ||
| + | | Kenneth Wilkins | National Institute of Health | Bethesda, MD, USA | | | ||
| + | | Ying Xiao | Penn Medicine, University of Pennsylvania | Philadelphia, PA, USA | | | ||
| + | | Qi Yang | IQVIA | Plymouth Meeting, PA, USA | | | ||
| - | **Current: None** | + | ---- |
| - | **Old/ Archive** | + | **Other members**\\ |
| - | * http://www.ohdsi.org/web/wiki/doku.php?id=documentation:next_cdm:clinical_trial | + | |
| - | Schedule: First & Third Friday of every month (intended). | + | ^ Name ^ Organization ^ Location ^ |
| + | | Eldar Allakhverdiiev | Odysseus Data Services Inc. | Cambridge, MA, USA| ^ | ||
| + | | Sonia Araujo * | IQVIA | London, UK | | ||
| + | | Junn Bautista | Genentech | South San Francisco, CA, USA | | | ||
| + | | Elise Berliner | | | | ||
| + | | Ted Bebi | Medidata | Boston, MA, USA | | ||
| + | | Lina Clover | SAS | Raleigh-Durham, NC, USA | | ||
| + | | Alexander Davydov | Odysseus Data Services Inc. | Cambridge, MA, USA | | ||
| + | | Shawn Dolley | Open Global Health | Arlington, Virginia, USA | | ||
| + | | Rhonda Facile | CDISC | Austin, Texas, USA | | ||
| + | | Stephen Fortin | | | | ||
| + | | Vojtech Huser | National Library of Medicine,\\ National Institutes of Health | Bethesda, MD, USA | | ||
| + | | Michael Kallfelz | Odysseus Data Services Inc. | Berlin, Germany | [[https://www.linkedin.com/in/michael-kallfelz/|{{:wiki:linkedinicon.png?20}}]] | | ||
| + | | Gregory Klebanov | Odysseus Data Services Inc. | Cambridge, MA, USA | | ||
| + | | Bess LeRoy | CDISC | Tucson, AZ, USA | | ||
| + | | James Liddil | M2Gen | Tampa, FL, USA | | ||
| + | | Maxim Moinat | The Hyve | Utrecht, The Netherlands | | ||
| + | | Alexandra Orlova | Odysseus Data Services Inc. | Cambridge, MA, USA | | ||
| + | | Joshua F. Ransom | BEKHealth Inc | Wayland, MA, USA | | ||
| + | | Chris Roeder | School of Medicine, University of Colorado | CO, USA | | ||
| + | | Anthony Sunjaya | The George Institute for Global Health,\\ UNSW Sydney | Sydney, NSW, Australia | | | ||
| + | | Emma Vos | The Hyve | Utrecht, The Netherlands| | ||
| + | | Andrew Williams | Tufts Institute for Clinical Research \\ and Health Policy Studies | Boston, MA, USA | | ||
| + | | Ariana Winder | Javara Research | State College, Pennsylvania, USA | [[https://www.linkedin.com/in/amwinder/|{{:wiki:linkedinicon.png?20}}]] | | ||
| + | | Stella Zhu | Bill & Melinda Gates Medical Research Institute | Seattle, WA, USA| | ||
| - | Next Meeting: (Date and Time): Feb 8, 2019 at 12pm Eastern Time US | + | * Past leads |
| - | Call in Number: | + | ---- |
| - | Meeting link: | + | |
| - | https://shawndolley.my.webex.com/shawndolley.my/j.php?MTID=m1d56eb457a30b8a73ffb4fcf50a32843 | + | |
| - | Meeting number: | + | |
| - | 628 790 972 | + | |
| - | Password: | + | |
| - | tr*l | + | |
| - | + | ||
| - | More ways to join | + | |
| - | Join by video system | + | |
| - | Dial 628790972@shawndolley.my.webex.com | + | |
| - | You can also dial 173.243.2.68 and enter your meeting number. | + | |
| - | Join by phone | + | **Want to contribute to the group?** [[https://ohdsi.org/join-the-journey/|Opt-in here]]. \\ |
| - | +1-510-338-9438 USA Toll | + | [[https://ohdsi.org/this-week-in-ohdsi/|Click here to catch up recent calls and job openings]] |
| - | Access code: 628 790 972 | + | ~~NOTOC~~ |
projects/workgroups/clinicalstudy.1549655243.txt.gz · Last modified: 2019/02/08 19:47 by croeder
Page Tools
